Physician profile
Alexei Grom
NPI 1619997715
$63,001.37
in general payments reported to CMS, 2019-2025
12 companies · $8,185 in 2025
The $8,185 reported for 2025 was more than what 95% of Pediatric Rheumatology providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,074 · 2020: $2,164 · 2021: $2,921 · 2022: $2,911 · 2023: $20K · 2024: $21K · 2025: $8,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Travel and Lodging: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $1,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,851.48 |
| Travel and Lodging | $12,532.92 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,745.80 |
| Food and Beverage | $1,801.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $31,383.94 | 2019-2025 | |
| Swedish Orphan Biovitrum Ab | $21,221.93 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $7,708.40 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $2,200.00 | 2024 | Arcalyst |
| Abbvie INC. | $256.42 | 2019-2025 | |
| Amgen INC. | $103.71 | 2019-2025 | Enbrel, Avsola, Amjevita |
| Glaxosmithkline, LLC. | $31.44 | 2020-2023 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $31.39 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.49 | 2023 | Xatmep |
| Genentech USA, INC. | $16.40 | 2025 | Actemra |
| Sandoz INC. | $15.19 | 2023 | Hyrimoz |
| Pfizer INC. | $15.06 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexei Grom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.